Filing summary
Issuer discrepancy: The request identifies Crescent Biopharma, Inc., but the supplied Form 10-Q is for GlycoMimetics, Inc. (Nasdaq: GLYC). It covers the quarter ended September 30, 2021, and was signed November 2, 2021. The financial statements are unaudited.
Business context and financial position
GlycoMimetics is a clinical-stage biotechnology company with no approved drugs or commercial product revenue. Its lead candidate, uproleselan, is in a Phase 3 trial for relapsed/refractory acute myeloid leukemia (AML). The company reported $101.9 million in cash and cash equivalents at September 30, 2021, down from $137.0 million at December 31, 2020. Total liabilities were $11.4 million, including $2.2 million in lease liabilities; the filing reports no borrowings.
Key financial metrics
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0.09 million | $1.00 million | $1.14 million | $10.00 million |
| Research and development expense | $13.28 million | $10.67 million | $34.60 million | $33.21 million |
| General and administrative expense | $4.14 million | $4.06 million | $12.57 million | $12.73 million |
| Net loss | $17.33 million | $13.72 million | $46.01 million | $35.46 million |
| Net loss per share | $0.34 | $0.29 | $0.90 | $0.79 |
| Cash used in operating activities | Not stated for quarter | Not stated for quarter | $44.68 million | $29.56 million |
Margins are not meaningful for this pre-commercial company. For the nine months, investing activities used $0.01 million and financing provided $9.58 million, primarily from at-the-market (ATM) stock sales. Cash declined by $35.11 million. The company sold 2.52 million shares through its ATM in the period for $9.6 million net proceeds; approximately $86.3 million of authorized ATM capacity remained.
Changes and notable items
- Revenue fell 89% for the first nine months versus 2020, when it included a $9.0 million Apollomics upfront payment and a $1.0 million milestone. 2021 revenue primarily reflected $1.1 million from clinical-supply sales to Apollomics.
- Nine-month net loss increased 30%; operating expenses rose 3%. Q3 R&D expense increased 24%, driven mainly by uproleselan clinical development and manufacturing, and GMI-1687 toxicity studies.
- Interest income fell to $15,692 for the nine-month period from $476,879, reflecting lower average cash balances and interest rates.
- In August 2021, the company appointed a new CEO and granted him options, including performance-based awards tied to FDA approval and first commercial sale of uproleselan. The filing also describes recruiting and legal costs related to the CEO transition.
Outlook, risks, and contingencies
- Management expected to complete enrollment in the global Phase 3 uproleselan trial by year-end 2021 and, assuming timely enrollment, anticipated preliminary data after year-end 2022. Enrollment had returned to forecasted levels after early pandemic delays, but COVID-19 and variants could still affect trial completion.
- The filing gives two cash-runway formulations: the notes say available funds should cover at least 12 months from filing; MD&A estimates funding into the first half of 2023, excluding potential business-development proceeds and additional financing. These estimates depend on assumptions and may prove wrong.
- Management expects continued operating losses and negative operating cash flows, with increased spending anticipated for clinical trials, manufacturing, regulatory preparation, and pipeline development. Additional financing may be needed; it may not be available on acceptable terms and equity financing could dilute shareholders.
- Apollomics may owe up to approximately $179 million in additional milestones plus tiered royalties, but payments depend on development and commercial outcomes and are uncertain. The company has no other committed external liquidity source.
- The company reported no material legal proceedings, no material changes to its stated risk factors, and no off-balance-sheet arrangements. Disclosure controls were deemed effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the filing issuer: the supplied document is GlycoMimetics, Inc., not Crescent Biopharma, Inc.
- Track Phase 3 uproleselan enrollment, trial completion, and data timing against management’s stated expectations.
- Assess whether the projected cash runway remains achievable given operating cash burn, clinical and manufacturing spending, and financing needs.
- Verify future ATM share sales and dilution, and whether Apollomics development milestones or supply revenue materialize.
- Review the full risk-factor disclosures for clinical, regulatory, financing, and COVID-19-related uncertainties.